How had Indian Pharma responded to the challenges brought on by the Covid19 crisis and the inability to connect with doctors and other Rx influencers? Is it back to business-as-usual or have some companies learned from their mistakes and become digital savvy? How will Indian Pharma cope with the possibility of another lockdown and meeting restrictions looming in view of the rising Omicron wave?

BrandStorm & FFE

A peek into BrandStorm and FFE 2015 in Pictures and Videos

Does Public-Private Partnership Benefit The Public?

Does This Public-Private Partnership Benefit The Public?” (Tuesday, July...

Time for Pharma to Re-think its Way of Working

https://www.youtube.com/watch?v=BOO_CNxEzwQ Too many Medical Reps are chasing too few doctors,...

IMS Health Market Reflection Report for September 2016

The Indian Pharmaceutical Market (IPM) was valued at Rs. 10,278 crs in the month of September 2016 clocking a strong 10% growth over same period last year (SPLY). On a MAT September basis, the industry was valued at Rs. 111,022 crores and reflected a 13% growth with volumes contributing around 40% of this growth and New Introductions playing an important role with around 38% contribution to the overall growth.